Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Med Rep ; 24(2)2021 Aug.
Article in English | MEDLINE | ID: mdl-34109426

ABSTRACT

As is well known, dexmedetomidine (DEX) serves a neuroprotective role in cerebral ischemia­reperfusion (CIR) injury, and microRNA (miR)­199a has been re­ported to be associated with IR injury. However, the association between DEX and miR­199a in CIR injury remains unknown. Thus, the aim of the present study was to verify whether the neuroprotective effect of DEX on cerebral ischemia­reperfusion rats is associated with miR­199a. A rat model of CIR was established, and the modified neurological severity score (mNSS) was evaluated. The effect of DEX on the patholog­ical structure of the cerebral cortex in CIR rats was observed by hematoxylin and eosin and Nissl staining. Reverse transcription­quantitative PCR was used to analyze the expression levels of miR­199a in brain tissue following intracerebroventricular injection of miR­199a antagomir. The co­expression of NeuN and microtubule­associated proteins 1A/1B light chain 3B in the cerebral cortex was analyzed by immunofluorescence staining. Western blotting and immunohistochemistry were performed to analyze the expression of autophagy­associated proteins in the brain tissue. DEX inhibited the expression of miR­199a, decreased the mNSS and improved pathological damage to the cerebral cortex. DEX also inhibited autophagy and expression levels of associated proteins and decreased nerve cell injury. In conclusion, DEX inhibited expression of miR­199a and improved neurocyte injury induced by CIR.


Subject(s)
Brain Ischemia/drug therapy , Brain Ischemia/genetics , Dexmedetomidine/pharmacology , MicroRNAs/genetics , Neuroprotective Agents/pharmacology , Reperfusion Injury/drug therapy , Reperfusion Injury/genetics , Animals , Antigens, Nuclear/metabolism , Beclin-1/metabolism , Brain Ischemia/etiology , Brain Ischemia/pathology , Caspase 3/metabolism , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Dexmedetomidine/administration & dosage , Disease Models, Animal , Infarction, Middle Cerebral Artery/complications , Injections , Male , MicroRNAs/antagonists & inhibitors , MicroRNAs/metabolism , Microtubule-Associated Proteins/metabolism , Nerve Tissue Proteins/metabolism , Neurons/drug effects , Neuroprotective Agents/administration & dosage , RNA-Binding Proteins/metabolism , Rats, Sprague-Dawley , Reperfusion Injury/etiology , Reperfusion Injury/pathology
2.
Med Sci Monit ; 25: 121-127, 2019 Jan 05.
Article in English | MEDLINE | ID: mdl-30610183

ABSTRACT

BACKGROUND The aim of this study was to investigate the protective effect of ß-casomorphin-7 (ß-CM-7) and its possible mechanisms on acute kidney injury (AKI). MATERIAL AND METHODS Rats were randomly divided into a sham group, a cecal ligation and puncture (CLP) group, and a CLP+ß-CM-7 group. Kidney index, kidney function, and histopathology changes were assessed. The expression of neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (Kim-1), nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (IκBα), and p-IκBα in kidney tissues were detected by Western blotting. Inflammatory and oxidative stress factors were detected by ELISA kits. RESULTS The results showed that treatment with ß-CM-7 reduced the levels of creatinine (Cre), blood urea nitrogen (BUN), NGAL, and Kim-1 induced by CLP, weakening the pathological damage. In the CLP + ß-CM-7 group, the tumor necrosis factor-α (TNF-α) level and the DNA-binding activity of NF-κB p65 were significantly reduced and the interleukin-10 (IL-10) level was significantly increased compared with the CLP group. ß-CM-7 decreased the expression of p-IκBα/IκBα. In addition, ß-CM-7 increased the activity of superoxide dismutase (SOD) and decreased the level of malondialdehyde (MDA) in kidney tissue. CONCLUSIONS ß-CM-7 attenuated sepsis-induced AKI through reducing inflammation and oxidative stress and by inhibition of nuclear factor (NF)­κB activities. This study provides a new therapeutic agent for attenuating sepsis-induced kidney injury.


Subject(s)
Acute Kidney Injury/physiopathology , Endorphins/pharmacology , NF-kappa B/metabolism , Peptide Fragments/pharmacology , Acute Kidney Injury/drug therapy , Animals , Blood Urea Nitrogen , Cecum/pathology , Cell Adhesion Molecules , Creatinine/metabolism , Endorphins/metabolism , Inflammation/pathology , Kidney/injuries , Kidney/pathology , Ligation , Lipocalin-2 , Male , Malondialdehyde/metabolism , NF-KappaB Inhibitor alpha , NF-kappa B/drug effects , Oxidative Stress , Peptide Fragments/metabolism , Rats , Rats, Sprague-Dawley , Sepsis/complications , Sepsis/drug therapy , Signal Transduction/drug effects
3.
Int Immunopharmacol ; 43: 53-61, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27940378

ABSTRACT

Neuroinflammation plays a key role in many neurodegenerative disorders, including postoperative cognitive decline (POCD). Growing evidence has demonstrated that activation of the peroxisome proliferator-activated receptor-γ (PPARγ) attenuates the inflammatory response and improves cognitive dysfunction associated with many neuropsychiatric disorders. We hypothesize that down-regulation of PPARγ is linked to neuroinflammation and the subsequent cognitive deficits observed in an animal model of POCD. In the present study, the POCD animal model was established by performing an exploratory laparotomy under isoflurane anesthesia in 20-month-old male C57BL/6 mice. Behavioral tests, inflammatory biomarkers, including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1ß, ionized calcium-binding adaptor molecule-1 (IBA1)-positive cells, as well as glial fibrillary acidic protein (GFAP)-positive cells and brain-derived neurotrophic factor (BDNF), were measured. Herein, we showed that surgery induced profound impairment in cognition that was associated with significant decreases in PPARγ and BDNF expression, and significant increases in IL-1ß, IBA1-positive cells, and GFAP-positive cells in the hippocampus. As expected, the PPARγ agonist pioglitazone attenuated the surgery-induced inflammatory changes and rescued the associated cognitive impairment. However, these beneficial effects were abolished by the PPARγ specific antagonist GW9662, suggesting a pivotal role of the PPARγ pathway in the pathogenesis of POCD. Taken together, our results provide evidence that down-regulation of PPARγ may be involved in neuroinflammation and subsequent POCD, and suggest that activation of PPARγ by pioglitazone may represent a new way to prevent or treat POCD.


Subject(s)
Cognitive Dysfunction/immunology , Hippocampus/immunology , Laparotomy , Microglia/drug effects , Neurogenic Inflammation/immunology , PPAR gamma/metabolism , Postoperative Complications/immunology , Aging/immunology , Anilides/pharmacology , Animals , Brain-Derived Neurotrophic Factor/metabolism , Cells, Cultured , Cognitive Dysfunction/etiology , Cognitive Dysfunction/prevention & control , Cytokines/metabolism , Disease Models, Animal , Humans , Inflammation Mediators/metabolism , Male , Mice , Mice, Inbred C57BL , Microglia/metabolism , Microglia/pathology , Neurogenic Inflammation/drug therapy , Neurogenic Inflammation/etiology , Pioglitazone , Postoperative Complications/drug therapy , Thiazolidinediones/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...